Guías Clínicas
97
Guías tam izaje, d iagn óstico y tratam ien to de l hepa toca rcinoma - Sociedad Chilena de Gastroenterología
Organization, International Agency for
Research on Cancer, WHO Press, 2015.
Adv Nutr. 2016;7:418-9.
20.- Ryerson AB, Eheman CR, Altekruse
SF, Ward JW, Jemal A, Sherman RL, et
al. Annual Report to the Nation on the
Status of Cancer, 1975-2012, Featuring
the Increasing Incidence of Liver Cancer.
Cancer. 2016;122:1312-37.
21.- Rahib L, Smith BD, Aizenberg R,
Rosenzweig AB, Fleshman JM,
Matrisian LM. Projecting Cancer
Incidence and Deaths to 2030: The
Unexpected Burden of Thyroid, Liver,
and Pancreas Cancers in the United
States. Cancer Res. 2014;74:2913-21.
22.- Singal AG, Mittal S, Yerokun OA,
Ahn C, Marrero JA, Yopp AC, et al.
Hepatocellular Carcinoma Screening
Associated with Early Tumor Detection
and Improved Survival Among Patients
with Cirrhosis in the United States. Am J
Med. 2017;130:1099-106.
23.- Zhang B, Yang B, Tang Z. Randomized
Controlled Trial of Screening for
Hepatocellular Carcinoma. J Cancer Res
Clin Oncol. 2004;130:417-22.
24.- Poustchi H, Farrell GC, Strasser SI,
Lee AU, Mccaughan GW, George J.
Feasibility of Conducting a Randomized
Control Trial for Liver Cancer
Screening: Is a Randomized Controlled
Trial for Liver Cancer Screening
Feasible or Still Needed? Hepatology.
2011;54:1998-2004.
25.- Mittal S, Kanwal F, Ying J, Chung R,
Sada YH, Temple S, et al. Effectiveness
of Surveillance for Hepatocellular
Carcinoma in Clinical Practice: A United
States Cohort. J Hepatol. 2016;65:1148-
54.
26.- Ungtrakul T, Mahidol C, Chun-On
P, Laohapand C, Siripongsakun S,
Worakitsitisatorn A, et al. Hepatocellular
Carcinoma Screening and Surveillance
in 2293 Chronic Hepatitis B Patients in
an Endemic Area. World J Gastroenterol.
2016;22:7806-12.
27.- Stravitz RT, Heuman DM, Chand N,
Sterling RK, Shiffman ML, Luketic VA,
et al. Surveillance for Hepatocellular
Carcinoma in Patients with Cirrhosis
Improves Outcome. Am J Med.
2008;121:119-26.
28.- Chan ACY, Poon RTP, Ng KKC, Lo CM,
Fan ST, Wong J. Changing paradigm
in the management of hepatocellular
carcinoma improves the survival benefit
of early detection by screening. Ann
Surg. 2008;247:666-73.
29.- Tong M, Sun H, Hsien C, Lu D.
Surveillance for Hepatocellular
Carcinoma Improves Survival in Asian-
American Patients with Hepatitis B:
Results from a Community-Based
Clinic. Dig Dis Sci. 2010;55:826-35.
30.- Tanaka H, Nouso K, Kobashi H,
Kobayashi Y, Nakamura SI, Miyake
Y, et al. Surveillance of hepatocellular
carcinoma in patients with hepatitis C
virus infection may improve patient
survival. Liver Int. 2006;26:543-51.
31.- Singal AG, Pillai A, Tiro J. Early
Detection, Curative Treatment, and
Survival Rates for Hepatocellular
Carcinoma Surveillance in Patients with
Cirrhosis: A Meta-analysis. PLoS Med.
2014;11:e1001624.
32.- Kansagara D, Papak J, Pasha AS,
O’Neil M, Freeman M, Relevo R, et al.
Screening for Hepatocellular Carcinoma
in Chronic Liver Disease: A Systematic
Review. Ann Intern Med. 2014;161:261-
9.
33.- Nowicki TK, Markiet K, Szurowska E.
Diagnostic Imaging of Hepatocellular
Carcinoma - A Pictorial Essay. Curr Med
Imaging Rev. 2017;13:140-53.
34.- Bruix J, Reig M, Sherman M. Evidence-
Based Diagnosis, Staging, and Treatment
of Patients with Hepatocellular
Carcinoma. Gastroenterology.
2016;150:835-53.
35.- Singal A, Volk ML, Waljee A, Salgia R,
Higgins P, Rogers MAM, et al. Metaanalysis:
Surveillance with ultrasound
for Early-Stage Hepatocellular
Carcinoma in patients with Cirrhosis.
Aliment Pharmacol Ther. 2009;30:37-47.
36.- Chou R, Cuevas C, Fu R, Devine B,
Wasson N, Ginsburg A, et al. Imaging
Techniques for the Diagnosis of
Hepatocellular Carcinoma: A systematic
Review and Meta-analysis. Ann Intern
Med. 2015;162:697-711.
37.- Trinchet JC, Chaffaut C, Bourcier V,
Degos F, Henrion J, Fontaine H, et
al. Ultrasonographic Surveillance of
Hepatocellular Carcinoma in Cirrhosis:
A Randomized Trial Comparing 3- and
6-Month Periodicities. Hepatology.
2011;54:1987-97.
38.- Wang JH, Chang KC, Kee KM,
Chen PF, Yen YH, Tseng PL, et al.
Hepatocellular Carcinoma Surveillance
at 4-vs. 12-Month Intervals for Patients
with Chronic Viral Hepatitis: A
Randomized Study in Community. Am J
Gastroenterol. 2013;108:416-24.
39.- Wong R, Ahmed A, Gish R. Elevated
Alpha-fetoprotein: Differential Diagnosis
Hepatocellular Carcinoma and Other
Disorders. Clin Liver Dis. 2015;19:309-
23.
40.- Gupta S, Bent S, Kohlwes J. Test
Characteristics of α-Fetoprotein for
Detecting Hepatocellular Carcinoma in
Patients with Hepatitis C. A Systematic
Review and Critical Analysis. Ann Intern
Med. 2003;139:46-50.
41.- Trevisani F, D’Intino PE, Morselli-
Labate AM, Mazzella G, Accogli E,
Caraceni P, et al. Serum α-Fetoprotein
for Diagnosis of Hepatocellular
Carcinoma in Patients with Chronic
Liver Disease: Influence of HBsAg
and Anti-HCV Status. J Hepatol.
2001;34:570-5.
42.- Aghoram R, Cai P, Dickinson JA.
Alpha-Foetoprotein and/or Liver
Ultrasonography for Screening of
Hepatocellular Carcinoma in patients
with Chronic Hepatitis B. Cochrane
Database Syst Rev. 2012;(9):CD002799.
43.- Singal AG, Conjeevaram HS, Volk
ML, Fu S, Fontana RJ, Askari F, et
al. Effectiveness of Hepatocellular
Carcinoma Surveillance in Patients with
Cirrhosis. Cancer Epidemiol Biomarkers
Prev. 2012;21:793-9.
44.- Chaiteerakij R, Addissie BD,
Roberts LR. Update on Biomarkers
of Hepatocellular Carcinoma.
Hepatocellular Carcinoma. Clin
Gastroenterol Hepatol. 2015;13:237-45.
45.- Lou J, Zhang L, Lv S, Zhang C, Jiang
S. Biomarkers for Hepatocellular
Carcinoma. Biomark Cancer. 2017;9:1-9.
46.- Heimbach J, Kulik LM, Finn R, Sirlin
CB, Abecassis M, Roberts LR, et al.
AASLD Guidelines for the Treatment of
Hepatocellular Carcinoma. Hepatology.
2018;67:358-80.
47.- Hennedige T, Venkatesh SK. Imaging of
Hepatocellular Carcinoma: Diagnosis,
Staging and Treatment Monitoring.
Cancer Imaging. 2012;12:530-47.
48.- Maruyama H, Yoshikawa M, Yokosuka
Gastroenterol. latinoam 2019; Vol 30, Nº 2: 64-106